In the 25 years since its creation, the Sanger Institute, Hinxton, UK, has distinguished itself as a leader in genomic sequencing and research. The institute contributed the largest single effort to decoding the first human genome, sequencing 8 of the 23 pairs of chromosomes. Since then, Sanger has contributed to reference genomes from the mouse to the mosquito to the gorilla. Now, it is asking the public to help decide which genomes to sequence next, as part of a 25th-anniversary campaign. Twenty of the 25 planned species genomes have been selected, with the remaining 5 voted on as part of the institute's "I'm a Scientist, Get Me Out of Here" campaign, which ran in late 2017. To attract the public's attention, scientists formed teams on the Wellcome Genome Campus, as well as the Natural History Museum in London and other institutions to champion individual species. All selected genomes will be new to science, never before having been sequenced. When finished, each sequence will become the reference genome for that species. The initiative is part of a larger project in which scientists from around the world plan to sequence all life forms on Earth. The reference genomes are expected to contribute to research on how species are responding to environmental pressures and what adaptations they have made to enable them to flourish. -Karyn Hede, News Editor
Australia struggles with genetic discrimination by insurers
A recent review article published online 16 October 2017 in the journal Public Health Genomics is raising alarm over life insurance industry regulations that the authors say could have a chilling effect on the entire genomic research enterprise in Australia.
In late 2016, the Australian Financial Services Council (FSC), an industry group, developed an insurance industry standard that appears to compel individuals to disclose whether they are even thinking about taking a genetic test. Senior coauthor Paul Lecaze of the School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, and his colleagues point to several concerns arising from the 2016 FSC Standard, in particular, the inadequacy of industry self-regulation. Lack of government oversight could chill the progress of genomic medicine in Australia, they suggest. Insurers may deny coverage or increase premiums for healthy people who carry a mutation that predisposes them to debilitating disease or possible early death. In the United States, the Genetic Information Nondiscrimination Act protects against genetic discrimination in the contexts of health insurance or employment. However, the law does not prohibit the use of genetic information to discriminate in provision of life insurance, disability insurance, or long-termcare insurance. Protecting genomic research participants from discrimination is critical for encouraging wide participation in genomic research, including the United States' own All of Us cohort, which aspires to sequence over 1 million participants as part of an overarching precision medicine effort. The public deserves transparency and some level of basic protection regarding the potential consequences of gaining knowledge about the genomic hand they've been dealt. 
